The discovery and development of HMG-CoA reductase inhibitors.

Regulation of the mevalonate pathway

Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · see citing works

The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis

Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 2,455 · see citing works

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159 · see citing works

All ras proteins are polyisoprenylated but only some are palmitoylated

Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775 · see citing works

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630 · see citing works

Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease.

(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-5-786_2 · Cited by 1,425 · see citing works

Receptor-Mediated Control of Cholesterol Metabolism

Brown, M. S., & Goldstein, J. L. (1976) · Science · doi:10.1126/science.174194 · Cited by 960 · see citing works

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.

Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954 · see citing works

Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity

Endo, A., Kuroda, M., & Tanzawa, K. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80996-9 · Cited by 800 · see citing works

HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia

Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760 · see citing works

Influence of nicotinic acid on serum cholesterol in man

Altschul, R., Hoffer, A., & Stephen, J. D. (1955) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(55)90070-9 · Cited by 726 · see citing works

Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity

Brown, M. S., & Goldstein, J. L. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.3.788 · Cited by 598 · see citing works

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557 · see citing works

Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase

Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556 · see citing works

Genetic and Pharmacological Suppression of Oncogenic Mutations in RAS Genes of Yeast and Humans

Schafer, W. R., Kim, R., Sterne, R. E., Thorner, J. W., Kim, S., & Rine, J. (1989) · Science · doi:10.1126/science.2569235 · Cited by 530 · see citing works

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.

Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J., & Brown, M. S. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.2.1194 · Cited by 421 · see citing works

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

Tsujita, Y., Kuroda, M., Shimada, Y., Tanzawa, K., ARAI, M., Kaneko, I., Tanaka, M., Masuda, H., Tarumi, C., Watanabe, Y., et al. (1986) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(86)90117-7 · Cited by 373 · see citing works

Regulation of Cholesterol Metabolism

Dietschy, J. M., & Wilson, J. D. (1970) · New England Journal of Medicine · doi:10.1056/nejm197005142822005 · Cited by 362 · see citing works

Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum

BROWN, A. G., Smale, T. C., King, T. J., Hasenkamp, R., & Thompson, R. H. (1976) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19760001165 · Cited by 360 · see citing works

Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor.

Habenicht, A. J. R., Glomset, J. A., & Ross, R. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70760-1 · Cited by 349 · see citing works

Regulation of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Activity in Human Fibroblasts by Lipoproteins

Brown, M. S., Dana, S. E., & Goldstein, J. L. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.7.2162 · Cited by 344 · see citing works

Modification of Metabolism and Distribution of Lipids by Ethyl Chlorophenoxyisobutyrate

THORP, J. M., & WARING, W. S. (1962) · Nature · doi:10.1038/194948a0 · Cited by 342 · see citing works

Regulation of Cholesterol Metabolism

Dietschy, J. M., & Wilson, J. D. (1970) · New England Journal of Medicine · doi:10.1056/nejm197005212822105 · Cited by 337 · see citing works

Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.

Ma, P. T. S., Gil, G., Südhof, T. C., Bilheimer, D. W., Goldstein, J. L., & Brown, M. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8370 · Cited by 334 · see citing works

Feedback Control of Mevalonate Synthesis by Dietary Cholesterol

Siperstein, M. D., & Fagan, V. M. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96879-1 · Cited by 332 · see citing works

Reduction of Blood Cholesterol in Man

POLLAK, O. J. (1953) · Circulation · doi:10.1161/01.cir.7.5.702 · Cited by 327 · see citing works

Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum.

Liscum, L., Finer-Moore, J. S., Stroud, R. M., Luskey, K. L., Brown, M. S., & Goldstein, J. L. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89764-2 · Cited by 308 · see citing works

Effect of cholesterol feeding and fasting on sterol synthesis in seventeen tissues of the rat

Dietschy, J. M., & Siperstein, M. D. (1967) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38921-5 · Cited by 296 · see citing works

Essential role for mevalonate synthesis in DNA replication

Quesney-Huneeus, V., Wiley, M. H., & Siperstein, M. D. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.10.5056 · Cited by 293 · see citing works

Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase

Endo, A. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00382a001 · Cited by 286 · see citing works

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin

Hoffman, W. F., Alberts, A. W., Anderson, P., Chen, J. S., Smith, R. L., & Willard, A. K. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00155a040 · Cited by 268 · see citing works

Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A Reductase

Endo, A., Tsujita, Y., KURODA, M., & Tanzawa, K. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11637.x · Cited by 263 · see citing works

Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia

Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050902 · Cited by 262 · see citing works

Abortions because of unavailability of prenatal diagnosis.

Hook, E. B., & Am, W. (1981) · PubMed · Cited by 261 · see citing works

Nucleotide sequence of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, a glycoprotein of endoplasmic reticulum

Chin, D. J., Gil, G., Russell, D. W., Liscum, L., Luskey, K. L., Basu, S. K., Okayama, H., Berg, P. R., Goldstein, J. L., & Brown, M. S. (1984) · Nature · doi:10.1038/308613a0 · Cited by 257 · see citing works

Evidence for modification of lamin B by a product of mevalonic acid.

Wolda, S. L., & Glomset, J. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68736-8 · Cited by 254 · see citing works

Inhibitory Effects on Lipid Metabolismn in Cultured Cells of ML‐236B, a Potent Inhibitor of 3‐Hydroxt‐3‐methylglutaryl‐Cornzyme‐A Reductase

KANEKO, O., Yoko, H.-S., & Endo, A. (1978) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1978.tb12380.x · Cited by 249 · see citing works

Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Chin, D. J., Luskey, K. L., Anderson, R. G. W., Faust, J. R., Goldstein, J. L., & Brown, M. S. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.4.1185 · Cited by 249 · see citing works

Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins.

Schmidt, R., Schneider, C. J., & Glomset, J. A. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90945-2 · Cited by 235 · see citing works

Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Endo, A. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.334 · Cited by 234 · see citing works

Therapeutic effects of ML-236B in primary hypercholesterolemia

Yamamoto, A., Sudo, H., & Endo, A. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90124-0 · Cited by 231 · see citing works

Regulation of Cholesterol Biosynthesis in Normal and Malignant Tissues

(1970) · Current topics in cellular regulation · doi:10.1016/b978-0-12-152802-7.50009-8 · Cited by 227 · see citing works

Cholesterol synthesis in the squirrel monkey: relative rates of synthesis in various tissues and mechanisms of control

Dietschy, J. M., & Wilson, J. D. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105706 · Cited by 223 · see citing works

Simvastatin

Todd, P. A., & Goa, K. L. (1990) · Drugs · doi:10.2165/00003495-199040040-00007 · Cited by 221 · see citing works

Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals

Endo, A., Tsujita, Y., Masao, K., & Tanzawa, K. (1979) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(79)90028-6 · Cited by 216 · see citing works

Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia

Havel, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., Lees, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-609 · Cited by 212 · see citing works

Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.

Grundy, S. M., & Vega, G. L. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34252-8 · Cited by 208 · see citing works

Prevention of Cyclic and Triton-induced Increases in Hydroxymethylglutaryl Coenzyme A Reductase and Sterol Synthesis by Puromycin

Kandutsch, A. A., & Saucier, S. E. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78226-x · Cited by 206 · see citing works

The ras oncogene--an important regulatory element in lower eucaryotic organisms

Gibbs, W. W., & Marshall, M. S. (1989) · Microbiological Reviews · doi:10.1128/mr.53.2.171-185.1989 · Cited by 205 · see citing works

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Tobert, J. A., Bell, G. D., Birtwell, J., James, I. M., Kukovetz, W. R., Pryor, J., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 204 · see citing works

Cholesterol Biosynthesis in Preparations of Liver from Normal, Fasting, X-irradiated, Cholesterol-fed, Triton, or Δ4-Cholesten-3-one-treated Rats

Bucher, N. L. R., McGarrahan, K., Gould, E., & Loud, A. V. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70285-8 · Cited by 199 · see citing works

Reduction of Serum Cholesterol in Heterozygous Patients with Familial Hypercholesterolemia

Mabuchi, H., Sakai, T., Sakai, Y., Yoshimura, A., Watanabe, A., WAKASUGI, T., Koizumi, J., & Takeda, R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303173081101 · Cited by 198 · see citing works

HMG CoA reductase inhibitors

Hunninghake, D. B. (1992) · Current Opinion in Lipidology · doi:10.1097/00041433-199202000-00005 · Cited by 196 · see citing works

Amplification of the gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not for the 53-kDa protein, in UT-1 cells.

Luskey, K. L., Faust, J. R., Chin, D. J., Brown, M. S., & Goldstein, J. L. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82087-0 · Cited by 195 · see citing works

Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and its mRNA in rat liver as studied with a monoclonal antibody and a cDNA probe.

Liscum, L., Luskey, K. L., Chin, D. J., Ho, Y. K., Goldstein, J. L., & Brown, M. S. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82085-7 · Cited by 195 · see citing works

Improved assay of 3-hydroxy-3-methylglutaryl coenzyme A reductase

Goldfarb, S., & Pitot, H. C. (1971) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39504-3 · Cited by 176 · see citing works

Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei.

Beck, L. A., Hosick, T. J., & Sinensky, M. S. (1988) · The Journal of Cell Biology · doi:10.1083/jcb.107.4.1307 · Cited by 175 · see citing works

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

Illingworth, D. R., & Sexton, G. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111618 · Cited by 170 · see citing works

Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial Hypercholesterolemia

(1986) · JAMA · doi:10.1001/jama.1986.03380200067023 · Cited by 168 · see citing works

Plasma mevalonate as a measure of cholesterol synthesis in man.

Parker, T. S., McNamara, D. J., Brown, C. D., Kolb, R., AHRENS, E. H., Alberts, A. W., Tobert, J. A., Chen, J., & Schepper, P. J. D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111495 · Cited by 167 · see citing works

Therapeutic response to lovasatain (Mevinolin) in nonfamilial hypercholesterolemia - A Multicenter study

Hunninghake, D. B., Larose, J., Palmer, R. H., & Leon, A. S. (1986) · JAMA · Cited by 166 · see citing works

Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus

Garg, A., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180204 · Cited by 158 · see citing works

Plasma cholesterol lowering action of bile acid binding polymers in experimental animals

Tennent, D. M., Siegel, H., Zanetti, M. E., Kuron, G. W., Ott, W., & Wolf, F. J. (1960) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41235-0 · Cited by 157 · see citing works

EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA

Mol, M. J. T. M., Leuven, J. A. G., Erkelens, D. W., Schouten, T. A., & Stalenhoef, A. F. H. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90598-2 · Cited by 156 · see citing works

Molecular cloning of 3-hydroxy-3-methylglutaryl coenzyme a reductase and evidence for regulation of its mRNA.

Chin, D. J., Luskey, K. L., Faust, J. R., MacDonald, R. J., Brown, M. S., & Goldstein, J. L. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7704 · Cited by 144 · see citing works

Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia

Illingworth, D. R. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-5-598 · Cited by 129 · see citing works

Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism

Vega, G. L., & Grundy, S. M. (1988) · Kidney International · doi:10.1038/ki.1988.125 · Cited by 128 · see citing works

Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.

Grundy, S. M., & Bilheimer, D. W. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2538 · Cited by 123 · see citing works

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins

Vega, G. L., Krauss, R. M., & Grundy, S. M. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00124.x · Cited by 120 · see citing works

Combination Drug Therapy for Familial Combined Hyperlipidemia

East, C. A., Bilheimer, D. W., & Grundy, S. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-1-25 · Cited by 118 · see citing works

Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase

Tsujita, Y., Kuroda, M., Tanzawa, K., KITANO, N., & Endo, A. (1979) · Atherosclerosis · doi:10.1016/0021-9150(79)90174-6 · Cited by 112 · see citing works

Influence of Combined Therapy with Mevinolin and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial Hypercholesterolemia

Grundy, S. M., Vega, G. L., & Bilheimer, D. W. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-339 · Cited by 106 · see citing works

Mode of interaction of .beta.-hydroxy-.beta.-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds

Nakamura, C. E., & Abeles, R. H. (1985) · Biochemistry · doi:10.1021/bi00327a014 · Cited by 105 · see citing works

Lipoprotein receptors, cholesterol metabolism, and atherosclerosis.

Goldstein, J., & Brown, M. S. (1975) · PubMed · Cited by 105 · see citing works

Cataracts in Patients Treated with Triparanol

Laughlin, R. C. (1962) · JAMA · doi:10.1001/jama.1962.03050300059020a · Cited by 100 · see citing works

Citrinin, an inhibitor of cholesterol synthesis.

Endo, A., & KURODA, M. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.841 · Cited by 99 · see citing works

Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in triton WR-1339-induced hyperlipidemia

Kuroda, M., Tanzawa, K., Tsujita, Y., & Endo, A. (1977) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(77)90238-7 · Cited by 88 · see citing works

Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover

Uauy, R. D., Vega, G. L., Grundy, S. M., & Bilheimer, D. W. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)80289-0 · Cited by 85 · see citing works

Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B

Vega, G. L., East, C. A., & Grundy, S. M. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90107-4 · Cited by 82 · see citing works

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

Hoeg, J. M., Maher, M. B., Zech, L. A., Bailey, K. R., Gregg, R. E., Lackner, K. J., Fojo, S. S., Anchors, M., Bojanovski, M., Sprecher, D. L., et al. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90733-2 · Cited by 82 · see citing works

The Effect of CS-514 on Serum Lipids and Apolipoproteins in Hypercholesterolemic Subjects

Nakaya, N. (1987) · JAMA · doi:10.1001/jama.1987.03390220086026 · Cited by 81 · see citing works

Hypolipidemic effects in monkeys of ML‐236B, a competitive inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase

Kuroda, M., Tsujita, Y., Tanzawa, K., & Endo, A. (1979) · Lipids · doi:10.1007/bf02533537 · Cited by 81 · see citing works

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia

Hunninghake, D. B., Knopp, R. H., Schonfeld, G., Goldberg, A. C., Brown, W. V., Schaefer, E. J., Margolis, S., Dobs, A. S., Mellies, M. J., Insull, W., et al. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90185-l · Cited by 77 · see citing works

THE INFLUENCE OF INTRAVENOUSLY ADMINISTERED SURFACE-ACTIVE AGENTS ON THE DEVELOPMENT OF EXPERIMENTAL ATHEROSCLEROSIS IN RABBITS

Kellner, A., Correll, J. W., & Ladd, A. T. (1951) · The Journal of Experimental Medicine · doi:10.1084/jem.93.4.385 · Cited by 71 · see citing works

Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids

Beck, G., Keßeler, K., Baader, E., Bartmann, W., Bergmann, A., Granzer, E., Jendralla, H., Kerékjártó, B. V., & Krause, R. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00163a010 · Cited by 68 · see citing works

A study of the Influence of mevalonic acid and its metabolites on the morphology of swiss 3T3 cells.

Schmidt, R., Glomset, J. A., Wight, T. N., Habenicht, A. J. R., & Ross, R. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.95.1.144 · Cited by 68 · see citing works

Regulation of Hmg-coa Reductase

(1985) · Elsevier eBooks · doi:10.1016/b978-0-12-564430-3.x5001-4 · Cited by 65 · see citing works

Lowering of Serum Lipid Concentrations

Goldsmith, G. A. (1960) · A M A Archives of Internal Medicine · doi:10.1001/archinte.1960.00270160010003 · Cited by 65 · see citing works

The Biosynthesis of Mevalonic Acid from 1-C14-Acetate by a Rat Liver Enzyme System

Knauss, H. J., Porter, J. W., & Wasson, G. W. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69680-2 · Cited by 62 · see citing works

Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia

Illingworth, D. R., & Bacon, S. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90589-3 · Cited by 62 · see citing works

Kinetic Analysis of the Reaction Catalyzed by Rat‐Liver 3‐Hydroxy‐3‐methylglutaryl‐coenzyme‐A Reductase Using Two Specific Inhibitors

Tanzawa, K., & Akira, E. N. D. O. (1979) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1979.tb13177.x · Cited by 61 · see citing works

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

Yuan, J., Tsai, M. Y., Hegland, J., & Hunninghake, D. B. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90017-w · Cited by 60 · see citing works

Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia

Mabuchi, H., KAMON, N., Fujita, H., Michishita, I., TAKEDA, M., Kajinami, K., Itoh, H., WAKASUGI, T., & Takeda, R. (1987) · Metabolism · doi:10.1016/0026-0495(87)90046-1 · Cited by 53 · see citing works

Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia

Illingworth, D. R. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.185 · Cited by 51 · see citing works

Preliminary report: Treatment of type 3 hyperlipoproteinemia with mevinolin

East, C. A., Grundy, S. M., & Bilheimer, D. W. (1986) · Metabolism · doi:10.1016/0026-0495(86)90106-x · Cited by 51 · see citing works

Reduction of Serum Cholesterol by Sodium Dextro-Thyroxine

Starr, P. (1960) · Archives of Internal Medicine · doi:10.1001/archinte.1960.00270180008002 · Cited by 51 · see citing works

Effects of simvastatin and probucol in hypercholesterolemia (simvastatin multicenter study group II)

Pietro, D. A., Alexander, S., Mantell, G., Staggers, J. E., & Cook, T. J. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90251-8 · Cited by 47 · see citing works

A role for isoprenoid lipids in the localization and function of an oncoprotein.

Rine, J., & Sh, K. (1990) · PubMed · Cited by 38 · see citing works

SYNVINOLIN IN HYPERCHOLESTEROLAEMIA

Olsson, A., Mölgaard, J., & Schenk, H. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90070-x · Cited by 37 · see citing works

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

HOOGERBRUGGE, N., Mj, M., van Dormaal, J. J., Rustemeijer, C., Muls, E., Stalenhoef, A. F. H., & Birkenhäger, J. C. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00229.x · Cited by 36 · see citing works

Mevalonolactone derivatives as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Sato, A., Noguchi, H., Mitsui, S., Kaneko, I., & SHIMADA, Y. (1980) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.28.1509 · Cited by 34 · see citing works

The prenylation of proteins

Glomset, J., Gelb, M. H., & Farnsworth, C. C. (1991) · Current Opinion in Lipidology · doi:10.1097/00041433-199104000-00010 · Cited by 33 · see citing works

Safety, Tolerability, and Efficacy of Simvastatin and Fenofibrate - A Multicenter Study

Ziegler, O., & Drouin, P. (2008) · Cardiology · doi:10.1159/000174683 · Cited by 29 · see citing works

Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme a reductase by the antibiotic citrinin

Tanzawa, K., Masao, K., & Endo, A. (1977) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(77)90126-6 · Cited by 23 · see citing works

Microbial hydroxylation of compactin (ML-236B) and monacolin K.

Yamashita, H., TSUBOKAWA, S., & Endo, A. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.605 · Cited by 23 · see citing works

Triton hypercholesteremia: cause or consequence of augmented cholesterol synthesis

BYERS, S. O., Friedman, M., & Sugiyama, T. (1963) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1963.204.6.1100 · Cited by 23 · see citing works

Improvement in the Regulation of Cellular Cholesterologenesis in Diabetes: the Effect of Reduction in Serum Cholesterol by Simvastatin

Owens, D., Stinson, J. C., Collins, P. B., Johnson, A., & TOMKIN, G. H. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01562.x · Cited by 18 · see citing works

SPECIFIC INHIBITION OF DESMOSTEROL SYNTHESIS BY ML-236B IN MOUSE LM CELLS GROWN IN SUSPENSION IN A LIPID-FREE MEDIUM

Doi, O., & Endo, A. (1978) · Japanese Journal of Medical Science and Biology · doi:10.7883/yoken1952.31.225 · Cited by 17 · see citing works

Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.

Yamamoto, A., Yamamura, T., Yokoyama, S., Sudo, H., & Matsuzawa, Y. (1984) · PubMed · Cited by 15 · see citing works

Specific Nonsterol Inhibitors of HMG-CoA Reductase

Endo, A. (1985) · Elsevier eBooks · doi:10.1016/b978-0-12-564430-3.50006-2 · Cited by 13 · see citing works

Two Japanese Kindreds of Familial Hypercholesterolemia Including Homozygous Cases. A Report of Cases, and Studies on Serum-Lipoproteins and Enzymes

Yamamoto, A., Endo, A., Kitano, Y., Okada, A., ISHIKAWA, K., Kuroshima, T., & Kaneko, I. (1978) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.17.230 · Cited by 11 · see citing works

The effects of an inhibitor of cholesterol biosynthesis triparanol (MER-29), in subjects with and without coronary artery disease.

Hollander, W., & Chobanian, A. V. (1959) · PubMed · Cited by 9 · see citing works

Nutrition and therapeutics

Nestel, P. J., & Eisenberg, S. (1992) · Current Opinion in Lipidology · doi:10.1097/00041433-199202000-00001 · Cited by 2 · see citing works

Nutrition and therapeutics: Editorial Overview

Nestel, P. J., & Grundy, S. M. (1990) · Current Opinion in Lipidology · doi:10.1097/00041433-199002000-00002 · Cited by 1 · see citing works

Triglycerides and cardiovascular disease

Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · see citing works

The role of natural product chemistry in drug discovery

Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381 · see citing works

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology

Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116 · see citing works

Natural products to drugs: natural product-derived compounds in clinical trials

Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,073 · see citing works

A Tale of Coronary Artery Disease and Myocardial Infarction

Nabel, E. G., & Braunwald, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112570 · Cited by 994 · see citing works

Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts

Aulchenko, Y. S., Janssens, A. C. J. W., Albert Hofman, D., Isaacs, A. J., Sijbrands, E. J. G., Witteman, J. C. M., van Duijn, C. M., Ripatti, S., Lindqvist, I., Perola, M., et al. (2008) · Nature Genetics · doi:10.1038/ng.269 · Cited by 846 · see citing works

An analysis of FDA-approved drugs: natural products and their derivatives

Patridge, E. V., Gareiss, P. C., Kinch, M. S., & Hoyer, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.009 · Cited by 836 · see citing works

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · see citing works

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions

Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 574 · see citing works

A historical perspective on the discovery of statins

Endo, A. (2010) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.86.484 · Cited by 550 · see citing works

Natural products to drugs: natural product derived compounds in clinical trials

Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 493 · see citing works

Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor

Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484 · see citing works

Rumen methanogens and mitigation of methane emission by anti-methanogenic compounds and substances

Patra, A. K., Park, T., Kim, M., & Yu, Z. (2017) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-017-0145-9 · Cited by 469 · see citing works

Dysregulation of the mevalonate pathway promotes transformation

Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurišica, I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910258107 · Cited by 416 · see citing works

Gut microbiota and cardiovascular disease: opportunities and challenges

Kazemian, N., Mahmoudi, M., Halperin, F. A., Wu, J. C., & Pakpour, S. (2020) · Microbiome · doi:10.1186/s40168-020-00821-0 · Cited by 392 · see citing works

Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport

Jia, L., Betters, J. L., & Yu, L. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142233 · Cited by 384 · see citing works

Bioactive Compounds from Marine Bacteria and Fungi

Debbab, A., Aly, A. H., Lin, W. H., & Proksch, P. (2010) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2010.00179.x · Cited by 366 · see citing works

Cardiac cachexia: A systematic overview

von Haehling, S., Lainščak, M., Springer, J., & Anker, S. D. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 351 · see citing works

Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine

Brusq, J.-M. G., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., & Issandou, M. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600020-jlr200 · Cited by 344 · see citing works

Non-lipid-related effects of statins

Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 332 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322 · see citing works

Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

Parihar, S. P., Guler, R., Khutlang, R., Lang, D. M., Hurdayal, R., Mhlanga, M., Suzuki, H., Marais, A. D., & Brombacher, F. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jit550 · Cited by 295 · see citing works

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works

Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats

Babu, P. S., & Srinivasan, K. (1997) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006819605211 · Cited by 282 · see citing works

Pharmacology of competitive inhibitors of HMg-CoA reductase

Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 275 · see citing works

Brain cholesterol turnover required for geranylgeraniol production and learning in mice

Kotti, T. J., Ramirez, D. M. O., Pfeiffer, B. E., Huber, K. M., & Russell, D. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600316103 · Cited by 259 · see citing works

Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells

Cafforio, P., Dammacco, F., Gernone, A., & Silvestris, F. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi036 · Cited by 249 · see citing works

The role of the LDL receptor in apolipoprotein B secretion

Twisk, J., Gillian‐Daniel, D. L., Oler, A. T., Wang, L., Barrett, P. H. R., & Attie, A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8623 · Cited by 245 · see citing works

Targeting tumor cell metabolism with statins

Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 240 · see citing works

Comprehensive LC−MSE Lipidomic Analysis using a Shotgun Approach and Its Application to Biomarker Detection and Identification in Osteoarthritis Patients

Castro‐Perez, J. M., Kamphorst, J. J., DeGroot, J., Lafeber, F. P. J. G., Goshawk, J., Yu, K., Shockcor, J. P., Vreeken, R. J., & Hankemeier, T. (2010) · Journal of Proteome Research · doi:10.1021/pr901094j · Cited by 238 · see citing works

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.

Soma, M. R., Donetti, E., Parolini, C., Mazzini, G., Ferrari, C., Fumagalli, R., & Paoletti, R. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.4.571 · Cited by 225 · see citing works

Clinical Pharmacokinetics of Pravastatin

Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 225 · see citing works

Direct vascular effects of HMG-CoA reductase inhibitors

Bellosta, S., Bernini, F., Ferri, N., Quarato, P., Canavesi, M., Arnaboldi, L., Fumagalli, R., Paoletti, R., & Corsini, A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00319-5 · Cited by 223 · see citing works

NPC1L1 and cholesterol transport

Betters, J. L., & Yu, L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.03.030 · Cited by 213 · see citing works

Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials

Zheng, X., Xu, Y.-L., Li, S., Liu, X., Hui, R., & Huang, X. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.010926 · Cited by 212 · see citing works

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230 · see citing works

Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy

Steinberg, D. H. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 201 · see citing works

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase

Blum, C. B. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90626-2 · Cited by 192 · see citing works

Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AβP (1–40) and (1–42) peptides

Arispe, N. J., & Doh, M. (2002) · The FASEB Journal · doi:10.1096/fj.02-0829com · Cited by 189 · see citing works

Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation

Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180 · see citing works

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate β-Amyloid-Induced Microglial Inflammatory Responses

Cordle, A. C., & Landreth, G. E. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2544-04.2005 · Cited by 177 · see citing works

Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside.

Steinberg, D., & Gotto, A. (1999) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.282.21.2043 · Cited by 191 · see citing works

The diabetogenic action of statins — mechanisms and clinical implications

Betteridge, D. J., & Carmena, R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.194 · Cited by 173 · see citing works

Mining the Metabiome: Identifying Novel Natural Products from Microbial Communities

Milshteyn, A., Schneider, J. S., & Brady, S. F. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.006 · Cited by 173 · see citing works

Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

Desager, J., & Horsmans, Y. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631050-00003 · Cited by 167 · see citing works

The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC.

Morikawa, S., Takabe, W., Mataki, C., Kanke, T., Itoh, T., Wada, Y., Izumi, A., Saitō, Y., Hamakubo, T., & Kodama, T. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.178 · Cited by 167 · see citing works

Red Wine Polyphenolics Increase LDL Receptor Expression and Activity and Suppress the Secretion of ApoB100 from Human HepG2 Cells

Pal, S., Ho, N., Santos, C., Dubois, P., Mamo, J. C. L., Allister, E. M., & Croft, K. D. (2003) · Journal of Nutrition · doi:10.1093/jn/133.3.700 · Cited by 165 · see citing works

Cholesterol and beyond - The role of the mevalonate pathway in cancer biology

Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188351 · Cited by 167 · see citing works

Human cholesterol metabolism and therapeutic molecules

Charlton-Menys, V., & Durrington, P. N. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2007.035147 · Cited by 162 · see citing works

Emerging roles of the intestine in control of cholesterol metabolism

Kruit, J. K. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i40.6429 · Cited by 161 · see citing works

Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage

Chaichana, K. L., Pradilla, G., Huang, J., & Tamargo, R. J. (2009) · World Neurosurgery · doi:10.1016/j.surneu.2009.05.027 · Cited by 157 · see citing works

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Han, J., Lee, S.-H., Yoo, N. J., Hyung, L. S., Moon, Y. J., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2525 · Cited by 156 · see citing works

A gift from nature: the birth of the statins

Endo, A. (2008) · Nature Medicine · doi:10.1038/nm1008-1050 · Cited by 152 · see citing works

Chronic Cholesterol Depletion Using Statin Impairs the Function and Dynamics of Human Serotonin1A Receptors

Shrivastava, S. K., Pucadyil, T. J., Paila, Y. D., Ganguly, S., & Chattopadhyay, A. (2010) · Biochemistry · doi:10.1021/bi100276b · Cited by 150 · see citing works

A green tea extract lowers plasma cholesterol by inhibiting cholesterol synthesis and upregulating the LDL receptor in the cholesterol-fed rabbit

Bursill, C. A., Abbey, M., & Roach, P. D. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.033 · Cited by 149 · see citing works

Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease

Jeong, A., Suazo, K. F., Wood, W. G., Distefano, M. D., & Li, L. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1458070 · Cited by 148 · see citing works

The role of ATP citrate-lyase in the metabolic regulation of plasma lipids

PEARCE, N. J., Yates, J. W., Berkhout, T. A., Jackson, B., Tew, D. G., Boyd, H., Camilleri, P., Sweeney, P. J., Gribble, A. D., Shaw, A. N., et al. (1998) · Biochemical Journal · doi:10.1042/bj3340113 · Cited by 144 · see citing works

Granulomas and Inflammation: Host-Directed Therapies for Tuberculosis

Ndlovu, H., & Marakalala, M. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00434 · Cited by 137 · see citing works

Policosanol Modulates HMG-CoA Reductase Activity in Cultured Fibroblasts

Menéndez, R. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00265-4 · Cited by 135 · see citing works

Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters.

Cho, I.-J., Ahn, J., Kim, S., Choi, M.-S., & Ha, T. (2008) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2007.12.140 · Cited by 130 · see citing works

Cholesterol-Lowering Activity of Naringenin via Inhibition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Acyl Coenzyme A:Cholesterol Acyltransferase in Rats

Lee, S., Park, Y. B., Bae, K., Bok, S., Kwon, Y., Lee, E. S., & Choi, M. (1999) · Annals of Nutrition and Metabolism · doi:10.1159/000012783 · Cited by 128 · see citing works

SOAT1 promotes mevalonate pathway dependency in pancreatic cancer

Oni, T. E., Biffi, G., Baker, L. A., Yuan, H., Tonelli, C., Somerville, T. D. D., Deschênes, A., Belleau, P., Hwang, C., Rivera, F. J. S., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192389 · Cited by 124 · see citing works

Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade

Gisterå, A., Ketelhuth, D. F. J., Malin, S., & Hansson, G. K. (2022) · Circulation Research · doi:10.1161/circresaha.122.320263 · Cited by 120 · see citing works

Prenylation-dependent Association of Ki-Ras with Microtubules

Thissen, J., Gross, J. M., Subramanian, K., Meyer, T., & Casey, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30362 · Cited by 117 · see citing works

Decanolides, 10-membered lactones of natural origin

Dräger, G., Kirschning, A., Thiericke, R., & Zerlin, M. (1996) · Natural Product Reports · doi:10.1039/np9961300365 · Cited by 115 · see citing works

Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats

Jeon, S.-M., Kim, H., Kim, H.-J., Do, G., Jeong, T., Park, Y. B., & Choi, M. (2006) · Translational research · doi:10.1016/j.trsl.2006.08.001 · Cited by 112 · see citing works

Lupin Peptides Lower Low-Density Lipoprotein (LDL) Cholesterol through an Up-regulation of the LDL Receptor/Sterol Regulatory Element Binding Protein 2 (SREBP2) Pathway at HepG2 Cell Line

Lammi, C., Zanoni, C., Scigliuolo, G. M., D’Amato, A., & Arnoldi, A. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf500795b · Cited by 112 · see citing works

Biosynthesis of Mevalonic Acid from Acetyl-CoA

Bochar, D. A., Freisen, J., Stauffacher, C. V., & Rodwell, V. W. (1999) · Elsevier eBooks · doi:10.1016/b978-0-08-091283-7.00035-7 · Cited by 109 · see citing works

Camphene, a Plant-Derived Monoterpene, Reduces Plasma Cholesterol and Triglycerides in Hyperlipidemic Rats Independently of HMG-CoA Reductase Activity

Vallianou, I., Peroulis, N., Pantazis, P., & Hadzopoulou‐Cladaras, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020516 · Cited by 108 · see citing works

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

Bischoff, H., Angerbauer, R., Bender, J., Bischoff, E., Faggiotto, A., Petzinna, D., Pfitzner, J., Porter, M. C., Schmidt, D. D., & Thomas, G. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00188-3 · Cited by 108 · see citing works

Inhibition of Growth of Methane-Producing Bacteria of the Ruminant Forestomach by Hydroxymethylglutaryl∼SCoA Reductase Inhibitors

Miller, T. L., & Wolin, M. J. (2001) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(01)70177-4 · Cited by 107 · see citing works

Statins: the new aspirin?

Veillard, N. R., & Mach, F. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012505 · Cited by 106 · see citing works

The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins

Murphy, C., Deplazes, E., Cranfield, C. G., & Garcia, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228745 · Cited by 109 · see citing works

Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan

Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 102 · see citing works

Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.

Hou, R.-H., & Goldberg, A. (2009) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2008.11.007 · Cited by 105 · see citing works

Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages

Namatame, I., Tomoda, H., Ishibashi, S., & Ōmura, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307757100 · Cited by 96 · see citing works

Cardiovascular risk scores do not account for the effect of treatment: a review

Liew, S. M., Doust, J. A., & Glasziou, P. (2011) · Heart · doi:10.1136/hrt.2010.220442 · Cited by 97 · see citing works

Single-molecule theory of enzymatic inhibition

Robin, T., Reuveni, S., & Urbakh, M. (2018) · Nature Communications · doi:10.1038/s41467-018-02995-6 · Cited by 95 · see citing works

Cardiology's 10 greatest discoveries of the 20th century.

Mehta, N. J., & Khan, I. A. (2002) · Europe PMC (PubMed Central) · Cited by 94 · see citing works

Pathways to Biomedical Discovery

Thagard, P. R. (2003) · Philosophy of Science · doi:10.1086/375465 · Cited by 93 · see citing works

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

Kajinami, K., Brousseau, M. E., Nartsupha, C., Ordovás, J. M., & Schaefer, E. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300278-jlr200 · Cited by 93 · see citing works

Statins: Then and Now

Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 94 · see citing works

Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice

Kosters, A., Frijters, R., Schaap, F. G., Vink, E., Plösch, T., Ottenhoff, R., Jirsa, M., Cuyper, I. M. D., Kuipers, F., & Groen, A. K. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00093-x · Cited by 92 · see citing works

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

Kajinami, K., Takekoshi, N., Brousseau, M. E., & Schaefer, E. J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.004 · Cited by 92 · see citing works

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

Lencz, T., & Malhotra, A. K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.28 · Cited by 91 · see citing works

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia

Naoumova, R. P., Marais, A. D., Mountney, J., Firth, J. C., Rendell, N. B., Taylor, G. W., & Thompson, G. R. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05649-1 · Cited by 89 · see citing works

Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway

Song, J., Deng, P., Stinnett, S. S., Epstein, D. L., & Rao, P. V. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0776 · Cited by 88 · see citing works

The biosynthesis of steroids and triterpenoids

Brown, G. D. (1998) · Natural Product Reports · doi:10.1039/a815653y · Cited by 88 · see citing works

Mechanisms of Action and Efficacy of Statins against Influenza

Mehrbod, P., Omar, A. R., Bejo, M. H., Haghani, A., & Ideris, A. (2014) · BioMed Research International · doi:10.1155/2014/872370 · Cited by 87 · see citing works

Naringin alters the cholesterol biosynthesis and antioxidant enzyme activities in LDL receptor-knockout mice under cholesterol fed condition

Kim, H., Oh, G. T., Park, Y. B., Lee, M., Seo, H., & Choi, M. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.08.026 · Cited by 87 · see citing works

Crystal Structure of Pseudomonas mevalonii HMG-CoA Reductase at 3.0 Angstrom Resolution

Lawrence, C. M., Rodwell, V. W., & Stauffacher, C. V. (1995) · Science · doi:10.1126/science.7792601 · Cited by 87 · see citing works

Farnesol signalling in Candida albicans – more than just communication

Polke, M., Leonhardt, I., Kurzai, O., & Jacobsen, I. D. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1337711 · Cited by 87 · see citing works

The Hepatitis Delta Virus Large Antigen Is Farnesylated Both in Vitro and in Animal Cells

Otto, J. C., & Casey, P. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.4569 · Cited by 86 · see citing works

Direct Effects of Statins on the Vascular Wall

Corsini, A., Pazzucconi, F., Arnaboldi, L., Pfister, P., Fumagalli, R., Paoletti, R., & Sirtori, C. R. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199805000-00017 · Cited by 86 · see citing works

Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study

Marcus, M. W., Müskens, R. P. H. M., Ramdas, W. D., Wolfs, R. C. W., de Jong, P. T. V. M., Vingerling, J. R., Albert Hofman, D., Stricker, B. H. C., & Jansonius, N. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029724 · Cited by 85 · see citing works

Reducing shell egg cholesterol content. I. Overview, genetic approaches, and nutritional strategies

Elkin, R. G. (2006) · World s Poultry Science Journal · doi:10.1017/s0043933906001206 · Cited by 85 · see citing works

Substrate-induced closure of the flap domain in the ternary complex structures provides insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl–CoA reductase

Tabernero, L., Bochar, D. A., Rodwell, V. W., & Stauffacher, C. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7167 · Cited by 85 · see citing works

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 878 · see citing works

HMG-CoA reductase inhibitors as potent cholesterol lowering drugs

Tsujita, Y. (1994) · Gordon and Breach Science Publishers eBooks · Cited by 2 · see citing works

Lipid-lowering drugs: discovery and development of HMG-CoA reductase inhibitors.

Tsujita, Y. (1995) · 生体の科学

HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia

Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760 · see citing works

The discovery of the HMG-CoA reductase inhibitors “statins”: A historical perspective

Endo, A. (2001) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.28.6_111